Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients.


Journal

Psychology, health & medicine
ISSN: 1465-3966
Titre abrégé: Psychol Health Med
Pays: England
ID NLM: 9604099

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 5 2 2019
medline: 4 4 2020
entrez: 5 2 2019
Statut: ppublish

Résumé

The aim of this study was to measure the prevalence of FCR among a sample of French lymphoma survivors and to determine factors associated with clinical levels of FCR. The study was conducted with two cross-sectional measures: sociodemographic and anxiety, depression as well as health-related quality of life (HRQoL) scores were measured at the baseline of the post-cancer period and FCR was evaluated during the first 3 years of survivorship. The prevalence of clinical levels of FCR (≥13) was evaluated by the Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF) among non- and Hodgkin lymphoma survivors undergoing prior first-line chemotherapy. Among 108 lymphoma survivors with an average follow-up of 1.6 years (range 0.3-3.0 years), clinical levels of FCR (≥13) were observed for 44.4% (n = 48). Multivariate analysis indicated that baseline anxiety and low quality of life were related to clinically significant FCR levels.

Identifiants

pubmed: 30714815
doi: 10.1080/13548506.2019.1574354
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

781-787

Auteurs

V Walburg (V)

a Faculty of Literature and Human Sciences , Catholic Institute of Toulouse , Toulouse , France.

M Rueter (M)

b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.
c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.

S Lamy (S)

b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.
c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.
d Department of Epidemiology, Health Economics and Public Health, Faculty of Medicine , University of Toulouse III Paul Sabatier , Toulouse , France.

G Compaci (G)

e Department of Hematology-Internal Medicine , Toulouse University Hospital, Cancer University Institute of Toulouse Oncopole , Toulouse , France.

M Lapeyre-Mestre (M)

b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.
c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.
f Laboratory of Medical and Clinical Pharmacology Faculty of Medicine , University III Paul Sabatier , Toulouse , France.
g INSERM CIC 1436, Clinical Investigation Center , Toulouse University Hospital , Toulouse , France.

G Laurent (G)

c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.
e Department of Hematology-Internal Medicine , Toulouse University Hospital, Cancer University Institute of Toulouse Oncopole , Toulouse , France.

F Despas (F)

b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.
c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.
f Laboratory of Medical and Clinical Pharmacology Faculty of Medicine , University III Paul Sabatier , Toulouse , France.
g INSERM CIC 1436, Clinical Investigation Center , Toulouse University Hospital , Toulouse , France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH